XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the ...

AI has been a buzzword in the pharmaceutical industry for almost a decade, with countless headlines promising to ...

Drug discovery has traditionally been slow, expensive and prone to failure, but AI and machine learning are set to change all ...

XtalPi has accrued a number of Big Pharma partners over the years, including Eli Lilly, which struck a $250 million deal in 2023 to use XtalPi’s tech to identify potential drug candidates that Lilly ...

A deal between Shenzhen-based XTalPi and US firm DoveTree shows Chinese biotech AI capabilities are gaining recognition.

Given the variability between labs and the unique nature of R&D work, custom, niche AI tools are going to become much more ...

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

A new cancer drug candidate developed by Lawrence Livermore National Laboratory, BridgeBio Oncology Therapeutics and ...

AstraZeneca has entered a strategic research collaboration with China's CSPC Pharmaceutical Group, aiming to accelerate the ...

LOS ANGELES, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Renovaro Inc.'s (NASDAQ:RENB) wholly owned subsidiary BioSymetrics has unveiled a proprietary AI-based zebrafish screening platform designed ...

Several experts are seeing that value of AI's total overhaul of healthcare, including beneficial additions such as generative ...

At stake is a business that is projected to grow exponentially in the next decade. The market for AI-assisted drug discovery could reach US$13 billion by 2032 from US$1.5 billion in 2023, Coherent ...